Provision and Increased Production of COVID-19 Response Products and Services

「In the LS (Life Science) Solutions business, sales increased owing to higher culture media sales resulting from increased use of the company’s culture media by major pharmaceutical companies, strong reagent sales as market conditions recovered, and increased contract manufacturing of clinical-trial materials for domestically produced COVID-19 vaccines in the pharmaceuticals business.」

「In the LS (Life Science) Solutions business, sales increased owing to higher sales of culture media and reagents as market conditions recovered in the life sciences business, as well as an increase in contract manufacturing of clinical-trial materials for domestically produced COVID-19 vaccines in the pharmaceuticals business.」

「In the pharmaceuticals business, contract manufacturing of clinical-trial materials for domestically produced vaccines for coronavirus disease (hereinafter referred to as “COVID-19”) contributed to results, but sales declined owing to the absence of patent licensing revenue recorded in the same period of the previous year.」

「In the pharmaceuticals business, sales increased, driven by the recovery in demand for antibacterial agents and contract manufacturing of clinical-trial materials for domestically produced COVID-19 vaccines.」

「In the pharmaceuticals business, sales increased, driven by the recovery in demand for antibacterial agents and contract manufacturing of clinical-trial materials for domestically produced COVID-19 vaccines.」

「In October 2022, FUJIFILM Toyama Chemical Co., Ltd. announced that it would install dual-use facilities that would manufacture biopharmaceuticals during normal times and switch to vaccine manufacturing during a pandemic. The company will provide pharmaceutical companies with contract process development and manufacturing services for biopharmaceuticals, and during a pandemic will support the rapid development and supply of domestically produced vaccines by pharmaceutical companies through these contract services.」

「Going forward, in addition to advancing development of the current pipeline and manufacturing and selling antibacterials such as penicillin and providing contract manufacturing services, we will focus on contract businesses including process development and contract manufacturing for mRNA vaccines, including nucleic acid-based drugs and next-generation novel coronavirus vaccine candidates.」

「Going forward, in addition to advancing development of the current pipeline and manufacturing and selling antibacterials such as penicillin and providing contract manufacturing services, we will focus on contract businesses including process development and contract manufacturing for mRNA vaccines, including nucleic acid-based drugs and next-generation novel coronavirus vaccine candidates.」

「In the Bio CDMO business, revenue increased substantially, partly because active pharmaceutical ingredient manufacturing for a COVID-19 vaccine candidate at the U.S. site contributed to performance.」

「In the pharmaceutical business, from the beginning of the fiscal year we established a new supply chain with FUJIFILM Wako Pure Chemical Corporation and cooperating companies in Japan and overseas to increase production of the anti-influenza drug Avigan® Tablets (generic name: favipiravir), which was expected to be approved as a treatment for COVID-19. Sales increased due to the Japanese government's requested addition of 164 million tablets to its national stockpile, licensing revenue from our partner, major Indian pharmaceutical company Dr. Reddy's Laboratories Ltd., and global medical supplies and pharmaceutical provider Global Response Aid, as well as overseas supply.」

「The domestic Phase III clinical trial of Avigan® Tablets in patients with COVID-19 achieved its primary endpoint, and in October 2020 we submitted an application for partial changes to the approved manufacturing and marketing particulars. We also entered into a contract with biotechnology company VLP Therapeutics JAPAN LLC for contract manufacturing of the formulation for a COVID-19 vaccine candidate.」

「In addition, through our U.S. operations, we entered into a contract with U.S. biotechnology company Novavax, Inc. to manufacture the drug substance for its COVID-19 vaccine candidate. Furthermore, as part of Operation Warp Speed (hereinafter, "OWS"), a public-private partnership project launched by the U.S. government to develop COVID-19 vaccines, we received approximately ¥27 billion in funding for purposes including the expansion of manufacturing facilities. We plan to manufacture drug substances for COVID-19 vaccine candidates supported by OWS, including Novavax's candidate.」

「In March 2020, we began a domestic Phase III clinical trial of the anti-influenza drug Avigan® Tablets (generic name: favipiravir) in patients with COVID-19. In the United States, we began a Phase II clinical trial in April 2020. We have already begun increasing production and, in cooperation with the government, will contribute to containing the spread of COVID-19, bringing the pandemic to an end, and improving public health in the future.」